IntelGenx Technologies (OTCMKTS:IGXT) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Saturday, November 25th.
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $2.00 price target on shares of IntelGenx Technologies in a research note on Tuesday, November 21st.
IntelGenx Technologies (IGXT) opened at $0.72 on Friday. IntelGenx Technologies has a 12 month low of $0.62 and a 12 month high of $1.09. The company has a debt-to-equity ratio of 1.53, a quick ratio of 2.65 and a current ratio of 2.65.
ILLEGAL ACTIVITY NOTICE: “IntelGenx Technologies (IGXT) Downgraded to Sell at ValuEngine” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2017/12/05/intelgenx-technologies-corp-igxt-downgraded-to-sell-at-valuengine.html.
IntelGenx Technologies Company Profile
IntelGenx Technologies Corp. is a drug delivery company focusing on the development of orally administered drug delivery products based on its oral drug delivery technologies. The Company is a provider of product development services for the pharmaceutical industry, including the branded and generic pharmaceutical markets.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for IntelGenx Technologies Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelGenx Technologies Corp. and related companies with MarketBeat.com's FREE daily email newsletter.